Patrizio Lancellotti1,2, Thomas M Suter3, Teresa López-Fernández4, Maurizio Galderisi5, Alexander R Lyon6, Peter Van der Meer7, Alain Cohen Solal8, Jose-Luis Zamorano9, Guy Jerusalem10, Marie Moonen1, Victor Aboyans11, Jeroen J Bax12, Riccardo Asteggiano13. 1. Department of Cardiology, GIGA Cardiovascular Sciences, University of Liège Hospital, CHU Sart Tilman, Avenue de L'Hòpital 1, Liège, Belgium. 2. Gruppo Villa Maria Care and Research, Anthea Hospital, VIA C. ROSALBA, 35/37 70124 BARI (BA) - Puglia, Italy. 3. Department of Cardiology, lnselspital, Bern University Hospital, University of Bern. 4. Department of Cardiology, La Paz University Hospital, IdiPAZ, CiberCV, Madrid, Spain. 5. Department of Advanced Biomedical Sciences, Federico II University Hospital, Naples, Italy. 6. Royal Brompton Hospital and Imperial College, Dovehouse Street, London, UK. 7. Department of Cardiology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ, The Netherlands. 8. UMR INSERM U-942 "BIOmarkers in CArdioNeuroVAScular diseases" Université Paris VII-Denis Diderot Assistance Publique-Hôpitaux de Paris Service de Cardiologie, Hôpital Lariboisière, 2 rue Ambroise-Paré, Paris, France. 9. University Alcala, Hospital Ramón y Cajal, Ciber CV, Madrid, Spain. 10. University of Liège Hospital, Medical Oncology, CHU Sart Tilman, Avenue de L'Hòpital 1, Liège, Belgium. 11. Department of Cardiology, Dupuytren University Hospital, Limoges, France. 12. Department of Cardiology, Leiden University Medical Center, The Netherlands. 13. Cardiologist in Practice, Corso Venezia 10, Turin, Italy.
Abstract
AIMS: Anticancer therapies have extended the lives of millions of patients with malignancies, but for some this benefit is tempered by adverse cardiovascular (CV) effects. Cardiotoxicity may occur early or late after treatment initiation or termination. The extent of this cardiotoxicity is variable, depending on the type of drug used, combination with other drugs, mediastinal radiotherapy, the presence of CV risk factors, and comorbidities. A recent position paper from the European Society of Cardiology addressed the management of CV monitoring and management of patients treated for cancer. METHODS AND RESULTS: The current document is focused on the basis of the Cardio-Oncology (C-O) Services, presenting their rationale, organization, and implementation. C-O Services address the spectrum of prevention, detection, monitoring, and treatment of cancer patients at risk of cardiotoxicity and/or with concomitant CV diseases. These services require a multidisciplinary approach, with the aims of promoting CV health and facilitating the most effective cancer therapy. CONCLUSION: The expected growing volume of patients with cancer at risk of developing/worsening CV disease, the advent of new technological opportunities to refine diagnosis, and the necessity of early recognition of cancer therapy-related toxicity mandate an integrative multidisciplinary approach and care in a specialized environment. This document from the ESC Cardio-Oncology council proposes the grounds for creating C-O Services in Europe based on expert opinion. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Anticancer therapies have extended the lives of millions of patients with malignancies, but for some this benefit is tempered by adverse cardiovascular (CV) effects. Cardiotoxicity may occur early or late after treatment initiation or termination. The extent of this cardiotoxicity is variable, depending on the type of drug used, combination with other drugs, mediastinal radiotherapy, the presence of CV risk factors, and comorbidities. A recent position paper from the European Society of Cardiology addressed the management of CV monitoring and management of patients treated for cancer. METHODS AND RESULTS: The current document is focused on the basis of the Cardio-Oncology (C-O) Services, presenting their rationale, organization, and implementation. C-O Services address the spectrum of prevention, detection, monitoring, and treatment of cancerpatients at risk of cardiotoxicity and/or with concomitant CV diseases. These services require a multidisciplinary approach, with the aims of promoting CV health and facilitating the most effective cancer therapy. CONCLUSION: The expected growing volume of patients with cancer at risk of developing/worsening CV disease, the advent of new technological opportunities to refine diagnosis, and the necessity of early recognition of cancer therapy-related toxicity mandate an integrative multidisciplinary approach and care in a specialized environment. This document from the ESC Cardio-Oncology council proposes the grounds for creating C-O Services in Europe based on expert opinion. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Jose A Alvarez-Cardona; Jordan Ray; Joseph Carver; Vlad Zaha; Richard Cheng; Eric Yang; Joshua D Mitchell; Keith Stockerl-Goldstein; Lavanya Kondapalli; Susan Dent; Anita Arnold; Sherry Ann Brown; Monica Leja; Ana Barac; Daniel J Lenihan; Joerg Herrmann Journal: J Am Coll Cardiol Date: 2020-11-10 Impact factor: 24.094
Authors: José Luis Zamorano; Christer Gottfridsson; Riccardo Asteggiano; Dan Atar; Lina Badimon; Jeroen J Bax; Daniela Cardinale; Antonella Cardone; Elizabeth A M Feijen; Péter Ferdinandy; Teresa López-Fernández; Chris P Gale; John H Maduro; Javid Moslehi; Torbjørn Omland; Juan Carlos Plana Gomez; Jessica Scott; Thomas M Suter; Giorgio Minotti Journal: Eur J Heart Fail Date: 2020-10-02 Impact factor: 15.534
Authors: G Curigliano; D Lenihan; M Fradley; S Ganatra; A Barac; A Blaes; J Herrmann; C Porter; A R Lyon; P Lancellotti; A Patel; J DeCara; J Mitchell; E Harrison; J Moslehi; R Witteles; M G Calabro; R Orecchia; E de Azambuja; J L Zamorano; R Krone; Z Iakobishvili; J Carver; S Armenian; B Ky; D Cardinale; C M Cipolla; S Dent; K Jordan Journal: Ann Oncol Date: 2020-02 Impact factor: 32.976
Authors: Muzna Hussain; Yuan Hou; Chris Watson; Rohit Moudgil; Chirag Shah; Jame Abraham; G Thomas Budd; W H Wilson Tang; J Emanuel Finet; Karen James; Jerry D Estep; Bo Xu; Bo Hu; Paul Cremer; Christine Jellis; Richard A Grimm; Neil Greenberg; Zoran B Popovic; Leslie Cho; Milind Y Desai; Steven E Nissen; Samir R Kapadia; Lars G Svensson; Brian P Griffin; Feixiong Cheng; Patrick Collier Journal: Am J Cardiol Date: 2020-09-28 Impact factor: 2.778